289483-92-7

Basic information

• Product Name: 6-Aminopyridine-3-sulfonyl chloride
• Synonyms: 6-Aminopyridine-3-sulfonyl chloride;6-Amino-3-pyridinesulfonyl Chloride
• CAS NO: 289483-92-7
• Molecular Formula: C₅H₅ClN₂O₂S
• Molecular Weight: 193
• Mol File: 289483-92-7.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-Aminopyridine-3-sulfonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Aminopyridine-3-sulfonyl chloride(289483-92-7)
• EPA Substance Registry System: 6-Aminopyridine-3-sulfonyl chloride(289483-92-7)

Safety Data

• Hazardous Substances Data: 289483-92-7(Hazardous Substances Data)

Usage

Uses

6-Amino-3-pyridinesulfonyl Chloride was used in discovery and structure activity relationship study of potent and selective covalent inhibitors of transglutaminase 2 for Huntington’s Disease.

Upstream product

• 504-29-0 2-aminopyridine 

Downstream Products

• 1306722-80-4 4-(6-acryloylaminopyridine-3-sulfonyl)piperazine-1-carboxylic acid benzyl ester 
• 1361224-54-5 2-(4-((2R)-4-((6-amino-3-pyridinyl)sulphonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol 
• 1361224-53-4 2-(4-((2S)-4-((6-amino-3-pyridinyl)sulphonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol 
• 1361224-48-7 2-(4-(4-((6-amino-3-pyridinyl)sulphonyl)-2-(1-propyn-1-yl)-1-piperazinyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol 
• 477739-45-0 C₂₃H₂₃FN₄O₅S₂ 

Relevant articles and documents

SULFONAMIDE-SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS DUB INHIBITORS

The present invention relates to a class of sulfonamide-substituted cyanopyrrolidines of Formula (Ia) and (Ib) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase L1 (UCHL1) and ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having utility in a variety of therapeutic areas including cancer and conditions involving mitochondrial dysfunction: (Formulae (Ia), (Ib)).

HEPATITIS B VIRAL ASSEMBLY EFFECTORS

Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.

Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease

Tissue transglutaminase 2 (TG2) is a multifunctional protein primarily known for its calcium-dependent enzymatic protein cross-linking activity via isopeptide bond formation between glutamine and lysine residues. TG2 overexpression and activity have been found to be associated with Huntington's disease (HD); specifically, TG2 is up-regulated in the brains of HD patients and in animal models of the disease. Interestingly, genetic deletion of TG2 in two different HD mouse models, R6/1 and R6/2, results in improved phenotypes including a reduction in neuronal death and prolonged survival. Starting with phenylacrylamide screening hit 7d, we describe the SAR of this series leading to potent and selective TG2 inhibitors. The suitability of the compounds as in vitro tools to elucidate the biology of TG2 was demonstrated through mode of inhibition studies, characterization of druglike properties, and inhibition profiles in a cell lysate assay.